JP Morgan Reinstates Neutral on Nektar Therapeutics, Announces $65 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 57.5%

Neg 0% Neu 57.5% Pos 0%

JP Morgan analyst Jessica Fye reinstates Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and announces $65 price target.